Development of an immunogenic cell death prognostic signature for predicting clinical outcome and immune infiltration characterization in stomach adenocarcinoma DOI Creative Commons
Ye Liu, Lijia Zhang, Lei Xue

и другие.

Aging, Год журнала: 2023, Номер unknown

Опубликована: Окт. 19, 2023

Stomach adenocarcinoma (STAD) is a common gastric histological cancer type with high mortality rate. Immunogenic cell death (ICD) plays key factor during carcinogenesis progress, whereas the prognostic value and role of ICD-related genes (ICDRGs) in STAD remain unclear. The MSigDB database collecting ICDRGs were selected by univariate Cox regression analysis LASSO algorithm to establish novel risk model. Kaplan-Meier survival indicated significant difference OS rate patients score stratification. ESTIMATE, CIBERSORT, single sample gene set enrichment (ssGSEA) algorithms conducted estimate immune infiltration landscape Subgroup tumor mutation burden also analyzed identify characteristics between groups. Differences therapeutic responsiveness chemotherapeutic drugs targeted high-risk group low-risk group. impact one ICDRG, GPX1, on proliferation, migration invasiveness was confirmed vitro experiments GC cells test reliability bioinformatics results. This study gives evidence involvement ICD process provides new perspective for further accurate assessment prognosis efficacy patients. remains collected

Язык: Английский

Cell death pathways: molecular mechanisms and therapeutic targets for cancer DOI Creative Commons
Shaohui Wang, Sa Guo, Jing Guo

и другие.

MedComm, Год журнала: 2024, Номер 5(9)

Опубликована: Сен. 1, 2024

Abstract Cell death regulation is essential for tissue homeostasis and its dysregulation often underlies cancer development. Understanding the different pathways of cell can provide novel therapeutic strategies battling cancer. This review explores several key mechanisms apoptosis, necroptosis, autophagic death, ferroptosis, pyroptosis. The research gap addressed involves a thorough analysis how these be precisely targeted therapy, considering tumor heterogeneity adaptation. It delves into genetic epigenetic factors signaling cascades like phosphatidylinositol 3‐kinase/protein kinase B/mammalian target rapamycin (PI3K/AKT/mTOR) mitogen‐activated protein kinase/extracellular signal‐regulated (MAPK/ERK) pathways, which are critical death. Additionally, interaction microenvironment with cells, particularly influence hypoxia, nutrient deprivation, immune cellular interactions, explored. Emphasizing strategies, this highlights emerging modulators inducers such as B lymphoma 2 (BCL2) homology domain 3 (BH3) mimetics, tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL), chloroquine, innovative approaches to induce ferroptosis provides insights therapy's future direction, focusing on multifaceted circumvent drug resistance. examination evolving underlines considerable clinical potential continuous necessity in‐depth exploration within scientific domain.

Язык: Английский

Процитировано

12
Lovastatin/SN38 co-loaded liposomes amplified ICB therapeutic effect via remodeling the immunologically-cold colon tumor and synergized stimulation of cGAS-STING pathway DOI
Yi Yang, Jialong Qi,

Jialin Hu

и другие.

Cancer Letters, Год журнала: 2024, Номер 588, С. 216765 - 216765

Опубликована: Фев. 25, 2024

Язык: Английский

Процитировано

10
Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot DOI Creative Commons

Yiman Han,

Xin Tian,

Jiaqi Zhai

и другие.

Frontiers in Cell and Developmental Biology, Год журнала: 2024, Номер 12

Опубликована: Май 7, 2024

Immunotherapy has emerged as a promising cancer treatment option in recent years. In immune “hot” tumors, characterized by abundant cell infiltration, immunotherapy can improve patients’ prognosis activating the function of cells. By contrast, “cold” tumors are often less sensitive to owing low immunogenicity tumor cells, an inhibitory microenvironment, and series immune-escape mechanisms. Immunogenic death (ICD) is cellular process facilitate transformation eliciting innate adaptive responses through release (or exposure to) damage-related molecular patterns. Accumulating evidence suggests that various traditional therapies induce ICD, including chemotherapy, targeted therapy, radiotherapy, photodynamic therapy. this review, we summarize biological mechanisms hallmarks ICD introduce some newly discovered technologically innovative inducers activate system at level. Furthermore, also discuss clinical applications combing with immunotherapy. This review will provide valuable insights into future development ICD-related combination therapeutics potential management for tumors.

Язык: Английский

Процитировано

9
Ginger-Derived Exosome-Like Nanoparticles Loaded With Indocyanine Green Enhances Phototherapy Efficacy for Breast Cancer DOI Creative Commons
Zhaoming Guo, Guqing Li,

Lanjun Shen

и другие.

International Journal of Nanomedicine, Год журнала: 2025, Номер Volume 20, С. 1147 - 1169

Опубликована: Янв. 1, 2025

Phototherapy has remarkable advantages in cancer treatment, owing to its high efficiency and minimal invasiveness. Indocyanine green (ICG) plays an important role photo-mediated therapy. However, it several disadvantages such as poor stability aqueous solutions, easy aggregation of molecules, short plasma half-life. This study aimed develop efficient nanoplatform enhance the effects We developed a novel bio-nanoplatform by integrating edible ginger-derived exosome-like nanoparticles (GDNPs) photosensitizer, ICG (GDNPs@ICG). GDNPs were isolated from ginger juice loaded with co-incubation. The size distribution, zeta potential, morphology, total lipid content, drug release behavior GDNPs@ICG characterized. photothermal performance, cellular uptake cytotoxicity, anti-tumor effects, mechanism action investigated both vitro vivo. taken up tumor cells via lipid-dependent pathway. When irradiated 808 nm NIR laser, generated levels ROS, MDA, local hyperthermia within tumor, which caused peroxidation ER stress, thus enhancing breast therapy effect. Furthermore, vivo studies demonstrated that engineered significantly inhibited growth presented limited toxicity. Moreover, detecting expression CD31, N-cadherin, IL-6, IFN-γ, CD8, p16, p21, p53 tissues, we found substantially reduced angiogenesis, metastasis, activated immune response, promoted cell senescence tumor. Our enhanced therapeutic effect could be alternative for precise phototherapy.

Язык: Английский

Процитировано

1
Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment DOI Open Access
Wenhao Luo, Jun Wang, Hao Chen

и другие.

Cancer Letters, Год журнала: 2023, Номер 576, С. 216423 - 216423

Опубликована: Сен. 30, 2023

Язык: Английский

Процитировано

13
Targeting acid ceramidase enhances antitumor immune response in colorectal cancer DOI Creative Commons
Yadu Vijayan,

Shirley James,

Viswanathan Arun

и другие.

Journal of Advanced Research, Год журнала: 2023, Номер 65, С. 73 - 87

Опубликована: Дек. 21, 2023

Acid ceramidase (hereafter referred as ASAH1) is an enzyme in sphingolipid metabolism that converts pro-survival ceramide into sphingosine. ASAH1 has been shown to be overexpressed certain cancers. However, the role of colorectal cancer still remain elusive The present study aimed understand how regulates (CRC) progression and resistance checkpoint inhibitor therapy. Both pharmacological genetic silencing was used study. In vitro experiments were done on human mouse CRC cell lines. vivo studies conducted NOD-SCID BALB/c mice models. combination tested using a syngeneic tumor model CRC. Transcriptomic metabolomic analyses effect silencing. cases, expression resulted induction immunological death (ICD) mitochondrial stress. (LCL-521), either monotherapy or with anti-PD-1 antibody, reduction tumors and, through type I II interferon response, activation M1 macrophages T cells, leading enhanced infiltration cytotoxic cells. Our findings supported LCL-521 ICIs, which enhances antitumor responses, can druggable target

Язык: Английский

Процитировано

12
Ultrasound-Guided Histotripsy Triggers the Release of Tumor-Associated Antigens from Breast Cancers DOI Open Access

Shengzhuang Tang,

Reliza McGinnis,

Zhengyi Cao

и другие.

Cancers, Год журнала: 2025, Номер 17(2), С. 183 - 183

Опубликована: Янв. 8, 2025

Background/Objectives: There is increasing evidence to indicate that histotripsy treatment can enhance the host anti-tumor immune responses both locally at targeting tumor site as well systemically from abscopal effects. Histotripsy a non-invasive ultrasound ablation technology mechanically disrupts target tissue via cavitation. A key factor contributing histotripsy-induced effects believed be release of tumor-specific antigens (TSAs) or tumor-associated (TAAs) induce systemic response. In this study, we studied effect on HER2, well-defined TAA for cancer immunotherapy. Methods: range doses administered HER2-postive mammary cells in an vitro cell culture system and ex vivo were applied. addition, single dose was used murine model. The released proteins, specifically cell-free supernatants pellets analyzed by BCA protein assay, ultra-performance liquid chromatography (UPLC) Western blot. Results: Our results showed could significantly trigger HER2 proteins current study. level actually higher than pellets, suggesting intracellular domain into extracellular compartment. Furthermore, proportionally more doses, indicating free histotripsy-dose-dependent. Conclusions: conclusion, have qualitatively quantitatively demonstrated triggers histotripsy-mediated provides important insights mechanism underlying its immunostimulation suggests potential TSA/TAA-based immunotherapies numerous types.

Язык: Английский

Процитировано

0
Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer DOI Creative Commons
Markéta Skaličková, Katerina Hadrava Vanova, Ondřej Uher

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 15

Опубликована: Янв. 9, 2025

Despite enormous progress, advanced cancers are still one of the most serious medical problems in current society. Although various agents and therapeutic strategies with anticancer activity known used, they often fail to achieve satisfactory long-term patient outcomes survival. Recently, immunotherapy has shown success patients by harnessing important interactions between immune system cancer. However, many these therapies lead frequent side effects when administered systemically, prompting treatment modifications or discontinuation or, severe cases, fatalities. New approaches like intratumoral immunotherapy, characterized reduced effects, cost, systemic toxicity, offer promising prospects for future applications clinical oncology. In context locally metastatic cancer, combining diverse immunotherapeutic other targeting multiple cancer hallmarks appears crucial. Such combination hold promise improving survival promoting a sustained response. This review aims provide overview approaches, specifically focusing on administration drugs cancers. It also explores integration modalities maximize Additionally, summarizes recent advances discusses novel outlining directions field.

Язык: Английский

Процитировано

0
Synthesis and evaluation of KX-01 analogs with an exploration of linker attachment points for antibody-drug conjugates DOI Creative Commons
Young‐Ho Oh,

Dao T. T. An,

Jaebeom Park

и другие.

Bioorganic & Medicinal Chemistry Letters, Год журнала: 2025, Номер unknown, С. 130114 - 130114

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Pincer‐Type Pt(II)‐NHC Antibody‐Drug Conjugate for HER‐2‐Targeted Chemoimmunotherapy DOI Creative Commons
Tao Huang,

Wei-Ta Huang,

G. M. Huang

и другие.

Advanced Healthcare Materials, Год журнала: 2025, Номер unknown

Опубликована: Фев. 14, 2025

Platinum-based chemotherapy drugs play an indispensable role in clinical cancer treatment, but exhibit considerable side effects due to their non-specific mechanism of killing cells and normal cells. In this regard, the use antibodies conjugated anti-cancer platinum complexes will enable better differentiation from Here, six pincer-platinum(II) NHC (N-heterocyclic carbene) are reported, one which has amino group on N-alkyl ligand. This platinum(II) complex is used as payload for platinum(II)-based antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER-2). Notably, ADC can specifically bind HER-2 antigen, distinguish target non-target cells, good anti-tumor activity vitro vivo.

Язык: Английский

Процитировано

0